insights_auto
Why is 1SAN down 3.28%?
Dive Deeperchevron_right
1SAN:BIT
Sanofi SA
€70.84
arrow_downward
-3.28%(-2.40) 1D
Oct 2, 5:35:27 PM GMT+2 · EUR
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 1SAN...
Open
€70.87
High
€71.28
Low
€69.79
Mkt. cap
85.17B
Avg. vol.
1.51K
Volume
7.40K
P/E ratio
21.73
52-wk high
€90.78
52-wk low
€69.79
EPS
€3.26
No. of employees
75K
Open
€70.87
High
€71.28
Low
€69.79
Mkt. cap
85.17B
Avg. vol.
1.51K
Volume
7.40K
P/E ratio
21.73
52-wk high
€90.78
52-wk low
€69.79
EPS
€3.26
No. of employees
75K
News stories
From web sources and news partners
AD HOC NEWS
·
1 hour ago
Jefferies keeps Buy on Sanofi stock at EUR 100 target
AD HOC NEWS
·
22 hours ago
Sanofi stock gains 1.02 percent as antibody deal advances pipeline
AD HOC NEWS
·
1 day ago
Sanofi expands Regeneron alliance: what it means for Sanofi stock
AD HOC NEWS
·
1 day ago
Sanofi stock after-hours at EUR 70.68: plus 0.21 percent
Profile
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of the Euro Stoxx 50 stock market index. In 2023, the company was ranked 89th in the Forbes Global 2000.
Sanofi engages in the research and development, manufacturing, and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. It is one of the world's largest producer of vaccines through its subsidiary Sanofi Pasteur. Wikipedia
About Sanofi SA
CEOBelén Garijo | Paul Hudson
Employees74.8K
Founded1973
HeadquartersParis, Île-de-France, France
SectorPharmaceutical industry
Websitesanofi.com
Last report
Jul 30, 2026
Fiscal period
Q2 2026
- Normalized EPS / Est. (EUR)
- GAAP EPS / Est. (EUR)
- / €1.90
Revenue / Est. (EUR)
12.30B / 10.89B
Fiscal Q2 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in EUR | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 13.17B | 12.20B | 11.24B | 12.30B |
Cost of goods sold | 3.41B | 3.63B | 3.06B | 2.89B |
Cost of revenue | 3.41B | 3.63B | 3.06B | 2.89B |
Research and development expenses | 1.83B | 2.29B | 1.75B | 2.23B |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 2.29B | 2.82B | 2.33B | 2.49B |
Operating expense | 5.97B | 6.84B | 5.94B | 6.82B |
Total operating expenses | 9.39B | 10.46B | 9.00B | 9.71B |
Operating income | 3.78B | 1.74B | 2.25B | 2.59B |
Other non operating income | - | 122.00M | -40.00M | -91.00M |
EBT including unusual items | 3.51B | -1.16B | 2.01B | 828.00M |
EBT excluding unusual items | 3.67B | 1.70B | 2.14B | 2.40B |
Income tax expense | 680.00M | -348.00M | 420.00M | 451.00M |
Effective tax rate | 19.38% | 30.13% | 20.85% | 54.47% |
Other operating expenses | 1.39B | 1.19B | 1.33B | 1.55B |
Net income | 2.80B | -801.00M | 1.61B | 343.00M |
Net profit margin | 21.28% | -6.56% | 14.35% | 2.79% |
Earnings per share | - | 1.53 | 1.88 | - |
Interest and investment income | 114.00M | 79.00M | 60.00M | 64.00M |
Interest expense | -227.00M | - | -138.00M | -153.00M |
Net interest expenses | -113.00M | 79.00M | -78.00M | -89.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 4.20B | 3.49B | 2.78B | 3.83B |
Gain or loss from assets sale | 266.00M | -79.00M | - | -9.00M |